These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16229991)

  • 1. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection.
    Giordano P; Song J; Pertel P; Herrington J; Kowalsky S
    Int J Antimicrob Agents; 2005 Nov; 26(5):357-65. PubMed ID: 16229991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
    Gyssens IC; Dryden M; Kujath P; Nathwani D; Schaper N; Hampel B; Reimnitz P; Alder J; Arvis P
    J Antimicrob Chemother; 2011 Nov; 66(11):2632-42. PubMed ID: 21896561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
    Lipsky BA; Giordano P; Choudhri S; Song J
    J Antimicrob Chemother; 2007 Aug; 60(2):370-6. PubMed ID: 17553812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.
    Malangoni MA; Song J; Herrington J; Choudhri S; Pertel P
    Ann Surg; 2006 Aug; 244(2):204-11. PubMed ID: 16858182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.
    Vick-Fragoso R; Hernández-Oliva G; Cruz-Alcázar J; Amábile-Cuevas CF; Arvis P; Reimnitz P; Bogner JR;
    Infection; 2009 Oct; 37(5):407-17. PubMed ID: 19768381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.
    Schaper NC; Dryden M; Kujath P; Nathwani D; Arvis P; Reimnitz P; Alder J; Gyssens IC
    Infection; 2013 Feb; 41(1):175-86. PubMed ID: 23180507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study).
    Weiss G; Reimnitz P; Hampel B; Muehlhofer E; Lippert H;
    J Chemother; 2009 Apr; 21(2):170-80. PubMed ID: 19423470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
    Tellado J; Woods GL; Gesser R; McCarroll K; Teppler H
    Surg Infect (Larchmt); 2002; 3(4):303-14. PubMed ID: 12697078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience.
    Rakkar S; Roberts K; Towe BF; Flores SM; Heyd A; Warner J
    Int J Clin Pract; 2001 Jun; 55(5):309-15. PubMed ID: 11452678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and skin structure infections: a meta-analysis of randomised controlled trials.
    Chen F; Zheng N; Wang Y; Wen JL; Tu WF; Du YQ; Lin JM
    Int J Clin Pract; 2013 Sep; 67(9):834-42. PubMed ID: 23952463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
    Finch R; Schürmann D; Collins O; Kubin R; McGivern J; Bobbaers H; Izquierdo JL; Nikolaides P; Ogundare F; Raz R; Zuck P; Hoeffken G
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1746-54. PubMed ID: 12019085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
    Roy S; Higareda I; Angel-Muller E; Ismail M; Hague C; Adeyi B; Woods GL; Teppler H;
    Infect Dis Obstet Gynecol; 2003; 11(1):27-37. PubMed ID: 12839630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis.
    Arrieta JR; Galgano AS; Sakano E; Fonseca X; Amábile-Cuevas CF; Hernández-Oliva G; Vivar R; González G; Torres A;
    Am J Otolaryngol; 2007; 28(2):78-82. PubMed ID: 17362810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical infections with enterococcus: outcome in patients treated with ertapenem versus piperacillin-tazobactam.
    Teppler H; McCarroll K; Gesser RM; Woods GL
    Surg Infect (Larchmt); 2002; 3(4):337-49. PubMed ID: 12697080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center.
    Siami FS; LaFleur BJ; Siami GA
    Clin Ther; 2002 Jan; 24(1):59-72. PubMed ID: 11833836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
    McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
    Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.
    Portier H; Brambilla C; Garre M; Paganin F; Poubeau P; Zuck P
    Eur J Clin Microbiol Infect Dis; 2005 Jun; 24(6):367-76. PubMed ID: 15944847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV.
    Kern WV; Marchetti O; Drgona L; Akan H; Aoun M; Akova M; de Bock R; Paesmans M; Viscoli C; Calandra T
    J Clin Oncol; 2013 Mar; 31(9):1149-56. PubMed ID: 23358983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
    Starakis I; Gogos CA; Bassaris H
    Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.